Stephanie L Goff
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stephanie L Goff as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:05 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05155033 · Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaNational Cancer Institute (NCI) · recruiting · Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma · principal investigator
- Ph2NCT02621021 · A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabNational Cancer Institute (NCI) · recruiting · Melanoma · principal investigator
- Ph2NCT01993719 · Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaNational Cancer Institute (NCI) · completed · Metastatic Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:05 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer.Nat Med · 2018643 citationsRCR 18.9
- mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer.J Clin Invest · 2020373 citationsRCR 14.0
- Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.J Clin Oncol · 2016349 citationsRCR 9.1
- Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.J Clin Oncol · 2020259 citationsRCR 9.5
- Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.J Clin Oncol · 2017243 citationsRCR 6.5
- Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.Lancet Oncol · 2017233 citationsRCR 6.7
- Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.J Clin Oncol · 2022172 citationsRCR 9.9
- 75 citationsRCR 6.8
- Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial.Nat Med · 202560 citationsRCR 10.3
- Improving Rates of Outpatient Influenza Vaccination Through EHR Portal Messages and Interactive Automated Calls: A Randomized Controlled Trial.J Gen Intern Med · 201837 citationsRCR 1.9